White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example

PH FDC SC

9154

Healthcar

Christian Jackisch · Federico Manevy · Suzanne Frank · Nicki Roberts · Jason Shafrin

We have released capacity in our chemotherapy units for other treatments; we have significantly reduced IV compounding costs; and we have reduced wastage

For patients, the much shorter administration and observation times have reduced the impact that undergoing cancer treatment has on their daily lives

The majority of our patients have been very happy to switch from IV treatment to PH FDC SC

The switching rate [from IV pertuzumab and trastuzumab to PH FDC SC] was approximately 70–80%, regardless of age or therapy setting (e.g., neoadjuvant, adjuvant, or metastatic)

Most patients appreciated the option of flexible appointment scheduling, including late in the afternoon after work, early in the morning before work, or even during their lunch break

We have never had issues with privacy arising from injections into the thigh

With PH FDC SC, treatment is in and out. This in turn enables me to think about it less, giving me more head space and as a result feels like a weight has been lifted from my shoulders. The harsh reality of being a cancer patient is no longer at the forefront of my mind as I no longer have to visit a cancer ward for hours on end

PH FDC SC is literally life-changing. I would not change it for the world

PH FDC SC saved a significant amount of time compared with IV infusions

Switching from IV pertuzumab and trastuzumab to PH FDC SC is likely to produce economic benefits for the treatment of HER2-positive breast cancer, relative to IV alternatives

Switching from IV pertuzumab and trastuzumab to PH FDC SC is likely to be both patient- and healthcare provider-preferred, as well as generating cost savings





